Skip to main content
Equibles

Samsara BioCapital, L.P.

Regulatory profile

From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.

Holder type
Unknown

Schedule 13D/13G stakes

Stakes of 5% or more disclosed on Schedule 13D or 13G, each on the filer's latest filing for the security. These are event-dated stakes, not the quarter-end 13F portfolio below.

Company Schedule Filed Shares % of class Status
PMVP PMV Pharmaceuticals, Inc. 13G 50d 7,577,467 9.9% Current
ELOX Eloxx Pharmaceuticals, Inc. 13G 3mo 403,586 9.9% Current
RANI Rani Therapeutics Holdings, Inc. 13D/A not restated by this amendment, the earlier 13D's purpose stands 5mo 5,661,481 5% Current
KLRS Kalaris Therapeutics, Inc. 13D/A not restated by this amendment, the earlier 13D's purpose stands 6mo 10,657,028 44.8% Current
STRO Sutro Biopharma, Inc. 13G 6mo 1,062,872 6.4% Current
SGP SpyGlass Pharma, Inc. 13G 9mo 2,109,953 6.3% Current
VTVT vTv Therapeutics Inc. 13D/A not restated by this amendment, the earlier 13D's purpose stands 11mo 246,484 6.2% Current
SRRK Scholar Rock Holding Corp 13D/A not restated by this amendment, the earlier 13D's purpose stands 1y 6,367,614 6.6% Current
MLYS Mineralys Therapeutics, Inc. 13D/A not restated by this amendment, the earlier 13D's purpose stands 1y 5,674,916 7.3% Current
NGNE Neurogene Inc. 13G/A 1y 1,717,127 11.6% Current
SEPN Septerna, Inc. 13G 2y 2,768,520 6.2% Unconfirmed since Oct 28, 2024

A 13D or 13G stays in force until its filer amends it and no amendment is due without a material change, so a stake with no filing in 24 months reads unconfirmed, never sold. An amendment reporting under 5% ends the filer's duty to amend, not necessarily the holding. Shares are restated onto today's split basis. Show 12 exited, below-5% or retired stakes

Portfolio style

Not measured yet. Quarters are measured from the first covered 13F quarter, once each filing window closes.

How the bands are measured

Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.

Clone Performance

Build a hypothetical price-return history from this filer's public 13F holdings.

View clone backtest

No Portfolio Data

No 13F holdings on record; this filer discloses its stakes on Schedule 13D/13G above.